Roivant Sciences (NASDAQ:ROIV - Get Free Report) had its price target increased by stock analysts at Guggenheim from $46.00 to $48.00 in a research note issued on Monday, Benzinga reports. The firm presently has a "buy" rating on the stock. Guggenheim's target price would suggest a potential upside of 19.78% from the company's previous close.
Other analysts have also recently issued reports about the stock. Jefferies Financial Group upped their target price on shares of Roivant Sciences from $42.00 to $52.00 and gave the company a "buy" rating in a report on Tuesday, September 8th. Wolfe Research cut shares of Roivant Sciences from an "outperform" rating to a "peer perform" rating in a research note on Monday, October 12th. HC Wainwright boosted their price objective on shares of Roivant Sciences from $47.00 to $48.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Roivant Sciences in a research note on Thursday, September 24th. Finally, UBS Group set a $55.00 target price on Roivant Sciences in a report on Wednesday, September 9th. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $46.82.
Get Our Latest Stock Analysis on ROIV
Roivant Sciences Stock Up 1.4%
NASDAQ ROIV opened at $40.07 on Monday. The company has a 50-day moving average price of $37.31 and a 200-day moving average price of $32.25. Roivant Sciences has a 52 week low of $19.96 and a 52 week high of $42.50. The firm has a market capitalization of $28.95 billion, a P/E ratio of -62.83 and a beta of 1.23.
Insiders Place Their Bets
In other Roivant Sciences news, CFO Richard Pulik sold 175,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 11th. The shares were sold at an average price of $41.85, for a total transaction of $7,323,750.00. Following the sale, the chief financial officer owned 222,046 shares in the company, valued at approximately $9,292,625.10. This trade represents a 44.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Melissa Epperly sold 17,750 shares of Roivant Sciences stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares in the company, valued at $539,839.40. This represents a 54.27% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 1,982,747 shares of company stock worth $74,398,784. Company insiders own 8.80% of the company's stock.
Institutional Inflows and Outflows
Several hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its stake in Roivant Sciences by 179.0% in the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company's stock worth $95,124,000 after acquiring an additional 1,724,588 shares during the last quarter. Maverick Capital Ltd. bought a new position in shares of Roivant Sciences during the 1st quarter valued at approximately $45,066,000. Assenagon Asset Management S.A. boosted its position in shares of Roivant Sciences by 18.2% during the 2nd quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company's stock valued at $295,965,000 after acquiring an additional 1,286,464 shares during the last quarter. Affinity Asset Advisors LLC grew its holdings in shares of Roivant Sciences by 64.7% in the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company's stock valued at $77,560,000 after purchasing an additional 1,100,000 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new position in shares of Roivant Sciences in the third quarter valued at $35,624,000. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences is a biopharmaceutical company that develops medicines through a network of subsidiary companies, which it calls “Vants.” These businesses focus on advancing drug candidates in areas such as immunology, oncology, neuroscience and rare diseases. Founded in 2014, Roivant has built and supported subsidiaries to develop treatments, manage clinical programs and pursue partnerships. Its portfolio has included both internally developed candidates and medicines licensed from other companies.
Recommended Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.
This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.